UNIVERSITY OF SOUTHAMPTON HOSPITAL TRUST.
Blood. 2015 Apr 16;125(16):2455-6. doi: 10.1182/blood-2015-03-630772.
In this issue of Blood, Byrd et al provide an important update on the prolonged efficacy and the limited and reducing toxicity of the single-agent Bruton tyrosine kinase inhibitor ibrutinib in chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma patients who are followed for a median time of 3 years from start of treatment.
在本期《Blood》中，Byrd 等人提供了关于慢性淋巴细胞白血病（CLL）或小淋巴细胞淋巴瘤患者的单药 Bruton 酪氨酸激酶抑制剂伊布替尼的长期疗效以及有限且减少的毒性的重要更新，这些患者自开始治疗起中位随访时间为 3 年。
